Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 673-a-675-a, 2005; 10.1373/clinchem.2004.045427
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Choi, W. W.L.
Right arrow Articles by Ritchie, J. C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Choi, W. W.L.
Right arrow Articles by Ritchie, J. C.
Related Collections
Right arrow Clinical Immunology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:673-675.)
© 2005 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Aberrant Thyroid Testing Results in a Clinically Euthyroid Patient Who Had Received a Tumor Vaccine

William W.L. Choi1, Sumathi Srivatsa2 and James C. Ritchie1,a

1 Department of Pathology, and Laboratory Medicine, and,
2 Division of Endocrinology and Metabolism, Department of Medicine, Emory University School of Medicine, Atlanta, GA

aAddress correspondence to this author at: F-147, Emory University Hospital, Department of Pathology and Laboratory Medicine, 1364 Clifton Road NE, Atlanta, GA 30322. Fax 404-712-4780; e-mail jritchi@emory.edu.

The first 20% of the full text of this article appears below.


To the Editor:

We describe here the first case of immunoassay interference from human anti-mouse antibodies (HAMAs) induced by a therapeutic anti-idiotypic antibody. A 76-year-old woman was referred to the Emory Endocrinology Clinic in May 2002 for evaluation of abnormal thyroid function tests. Between August 2001 and March 2002, her total triiodothyronine (T3) was 6.62 to >12.32 nmol/L, but her T3 uptake, total thyroxine (T4), free T4, thyroid-stimulating hormone (TSH), and thyroglobulin were within the appropriate reference intervals.

The patient had undergone a partial thyroidectomy in 1987 for toxic goiter and had been stable on thyroxine replacement with thyroid indices within the appropriate reference values since that time. In January 2000, she underwent a colon resection for colon carcinoma and received adjuvant chemotherapy with 5-fluorouracil until August 2000 and an investigational tumor vaccine (CeaVac) from February 2000 until April 2002. CeaVac is a monoclonal antibody generated in BALB/c mice against another antibody that binds to a highly restricted carcinoembryonic . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.